MedWatch

Novo's innovation hunter brings back abandoned project

A new collaboration to identify small molecules against diabetes and secondary complications provides the framework for Novo Nordisk's future bet on oral drugs based on small molecules - a research field the company originally gave up in 2007.

Foto: Novo Nordisk

Danish Novo Nordisk and German biotech firm and CRO Evotec have established a new partnership to discover and develop small molecule therapies against diabetes, obesity and other related diseases.

But although the alliance is one in many recent acquisition- or collaboration deals, the new agreement is more than just a partnership.

Læs hele artiklen

Få 14 dages fri adgang.
Det kræver intet kreditkort.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier